Try our Advanced Search for more refined results
In re Vaxart, Inc. Securities Litigation
Case Number:
3:20-cv-05949
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Akin Gump
- Baker Botts
- Baker McKenzie
- Berman Tabacco
- Bleichmar Fonti
- Boies Schiller
- Conrad Metlitzky
- Goodwin Procter
- Hagens Berman
- Hanson Bridgett
- Paul Hastings
- Robbins LLP
- Scott&Scott
- Thompson Hine
- Umhofer Mitchell
- Williams & Connolly
- Willkie Farr
- Wilson Elser
Companies
Sectors & Industries:
-
April 21, 2026
Armistice Capital Head Calls COVID Stock Rise 'Fun,' 'Lucky'
Armistice Capital's founder defended his hedge fund Tuesday from claims it pump-and-dumped $250 million in Vaxart stock during the COVID-19 pandemic, telling a California federal jury that he and his fund got "lucky" and that the stock's rapid surge was "fun."
-
April 21, 2026
Armistice Head Testifies He Accidentally Deleted Texts
Armistice Capital's founder, who is facing investor claims that the hedge fund dumped its artificially inflated shares in pharmaceutical company Vaxart for $250 million, told a California federal jury Monday that during a physical therapy session held over Skype, he accidentally deleted key text messages with another Armistice executive.
-
April 14, 2026
Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told
Hedge fund Armistice Capital and two of its executives exploited the COVID-19 pandemic to issue press releases that falsely inflated their controlling share in pharmaceutical company Vaxart, then dumped the shares for $250 million before the bottom fell out, investors told a California federal jury at the start of trial Tuesday.
-
July 08, 2025
Vaxart Investors Can Pursue Suit Over COVID Vax Claims
A California federal judge declined to grant an early win to the onetime controlling shareholder of Vaxart in an investor suit alleging it dumped stock at inflated prices following deceptive headlines about the biotechnology company's ability to produce a COVID-19 vaccine.
-
December 18, 2024
Vaxart Investors Win Class Cert. Over COVID Shot On 2nd Try
A California federal judge has certified a class of Vaxart investors accusing the biotechnology company's onetime controlling shareholder of dumping stock at inflated prices following deceptive headlines about a COVID-19 vaccine, saying the investors' revised motion fixes issues of predominance and the damages model.
-
December 09, 2024
Akin Gump 'Totally Messed Up' With Texts, Vaxart Judge Says
A California federal judge asked by Vaxart investors to impose sanctions over a hedge fund's deleted text messages in a case claiming Vaxart inflated its stock price with deceptive headlines about a COVID-19 vaccine said Monday that the fund's lawyers at Akin Gump "totally, totally messed up."
-
April 30, 2024
Vaxart Investors Want Sanctions Over Deleted Texts
A group of Vaxart investors asked a California federal judge to issue sanctions against Armistice Capital LLC, which previously controlled Vaxart and allegedly sold $267 million worth of its Vaxart shares at inflated prices, saying the hedge fund and its executives purposely deleted text messages integral to the investors' claims.
-
August 22, 2022
Vaxart Investors Seek Initial OK Of $12M Deal In Fraud Suit
A proposed class of investors in Vaxart has urged a California federal court to give its initial OK to a $12 million settlement with the biotechnology company over allegations it pumped its stock price with deceptive headlines about a COVID-19 vaccine, arguing that it's a favorable outcome for investors.
-
December 22, 2021
Vaxart Can't Ditch Claims Co. Lied To Investors About Vaccine
A California federal judge kept alive a proposed securities class action Wednesday claiming the biotechnology company Vaxart pumped up its stock price with deceptive headlines about a COVID-19 vaccine, but tossed with leave to amend claims against a hedge fund that sold shares in the wake of Vaxart's statements.
-
September 30, 2021
Vaxart Buried Investors In 'Avalanche Of B.S.,' Judge Says
U.S. District Judge Vince Chhabria appeared skeptical Thursday of Vaxart's efforts to ditch a proposed securities class action claiming the biotechnology company artificially inflated its stock price with an allegedly deceptive headline about producing a COVID-19 vaccine candidate, saying the defendants "buried the investors in an avalanche of B.S."